Biotechnology company developing first-in-class small-molecule medicines that precisely modulate the innate immune system to treat inflammation-driven diseases and cancer
Biotechnology company developing first-in-class small-molecule medicines that precisely modulate the innate immune system to treat inflammation-driven diseases and cancer. Its programs include NLRP3 inflammasome and STING-targeting therapeutics.